Theranos (2015): Journal investigation — Section 1099: Journal investigation

The Journal’s 2015 series, CMS inspection files, the SEC complaint, and two federal criminal trials in San Jose are the primary sources. They describe investor fraud proved to a jury, not a scientific mystery still waiting for a device. Theranos raised capital on the promise of decentralized, low-volume blood testing. A 2013 partnership with Walgreens put collection sites in stores and made the claim a consumer-facing fact, not only a Silicon Valley pitch.

Internal and later public records showed that many tests offered to patients were run on third-party analyzers, sometimes after diluting small samples, while the company’s own devices handled a narrower set. That gap is the factual core of the later fraud cases. Carreyrou’s October 2015 article, followed by more Journal reporting, forced the company into a defensive public posture. CMS inspected the Newark, California laboratory and in 2016 imposed sanctions, including a ban on Holmes’s operating labs for a period.

The FDA and CMS files, plus later SEC charges in March 2018, moved the story from a magazine dispute into the enforcement docket. The company dissolved in 2018 as the criminal case was prepared. Holmes’s trial (2021–2022) focused on what investors were told about technology, pharmaceutical-company validation, and the Department of Defense. The jury convicted on investor-fraud counts and acquitted or hung on others, including patient-related wire-fraud counts.